Objective: To evaluate effect on comorbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort. Background: The number patients having surgical procedures to treat obesity and obesity-related disease are increasing. Yet, population-based, long-term outcome studies are few. Weight, remission of type 2 diabetes mellitus, hypertension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory data were studied. Five-year follow-up was 100% (9774 eligible individuals) for comorbid diseases. Results: BMI decreased from 42.8 AE 5.5 to 31.2 AE 5.5 kg/m 2 at 5 years, corresponding to 27.7% reduction in total body weight. Prevalence of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.7%-19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) was reduced. Greater weight loss was a positive prognostic factor, whereas increasing age or BMI at baseline was a negative prognostic factor for remission. The use of antidepressants increased (24.1%-27.5%). Laboratory status was improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol and 41.8% to 37.7%, respectively. Conclusions: In this nationwide study, gastric bypass resulted in large improvements in obesity-related comorbid disease and sustained weight loss over a 5-year period. The increased use of antidepressants warrants further investigation.
, respectively (Table 1 ). In SOReg, data are prospectively collected at baseline before surgery, at surgery, after 6 weeks (for days 0-30), and at 1, 2, and 5 years of follow-up. All participants and follow-up rate of eligible patients are demonstrated in the STrengthening the Reporting of OBservational studies in Epidemiology diagram; however, as bariatric surgery has been continuously increasing during the past years in Sweden, only the 9774 patients operated in 2010 or earlier were eligible at 5 years. The nationwide PDR was established in 2005 and includes all dispensed prescription drugs, classified according to the World Health Organization Anatomical Therapeutic Chemical (ATC) classification system. Since prescription medications are subsidized by the Swedish public health system, very few patients obtain drugs from other sources than those who report to the PDR. Due to the 45.2% 5-year follow-up in SOReg, SOReg was cross-matched with PDR, allowing a 100% 1, 2, and 5-year follow-up of comorbid disease (see definition below). Data were extracted from PDR on April 30, 2015 (Fig. 1 ).
Studied Obesity-related Comorbid Diseases
Comorbid disease, type 2 diabetes mellitus (T2DM) (ATC code: A10A, A10B), hypertension (C02, C03, C08, C09), dyslipidemia (C10), or depression (N06A) was defined as an obesityrelated condition if the patient was in need of active pharmacological treatment according to both PDR and SOReg. Obstructive sleep apnea syndrome (OSAS) was defined as on-going treatment with continuous positive airway pressure (CPAP) registered in SOReg. As a waist circumference >102 cm in men and >88 cm in women have been associated with increased risks of cardiovascular disease, 9 these specific cut-off points were studied. We studied the following biochemical markers (normal values in parenthesis): glycated hemoglobin (HbA1c) ( 48 mmol/mol), fasting glucose [ 7 mmol/L (multiply by 18 for mg/dL)], triglycerides (TGs) [<1.7 mol/L (multiply by 88.5 for mg/dL)], low-density lipoprotein cholesterol (LDL-C) [<4.1 mol/L (multiply by 38.6 for mg/dL)], and high-density lipoprotein cholesterol (HDL-C) [>1.3 mol/L (multiply by 38.6 for mg/dL)].
Outcomes
Weight was analyzed at 1, 2, and 5 years postoperatively according to the SOReg study protocol, as was HbA1c, serum glucose, lipids (TG, LDL, and HDL), and blood pressure. Remission of comorbid disease was strictly defined as having discontinued pharmacological treatment (both PDR and SOReg and CPAP in the case of sleep apnea). Recurrent disease was present when participants, having the specific disease at baseline, were found to have relapsed after being free of disease at some time point. New onset of a disease was present when individuals, free of disease at baseline, were found to be pharmacologically treated during follow-up.
Covariates
Analysis of weight change was performed for men and women. All analyses concerning remission of comorbidities were adjusted for sex, age at surgery, preoperative BMI, and present total weight loss (at 1, 2, and 5 years). For T2DM, HbA1c at baseline was also included in the multivariate analysis.
Statistical Analysis
Normally distributed data are presented as mean AE standard deviation (SD), and comparisons were made with Student t test. Differences in proportions were evaluated with chi-square test. In analysis of remission of comorbid disease, a logistic regression analysis was made with remission of each comorbid disease as dependent variable and the covariates described above. P < 0.05 was considered significant. In the statistical analyses, no imputation of data was performed.
Sensitivity Analysis
For comorbid disease, follow-up was 100% of all eligible patients (n ¼ 9774) in the PDR at 5-year follow-up; thus these are the studied patients. In addition, clinical data at 5 years was available for 2539 of 5623 eligible individuals (45.2%) in SOReg. No significant difference in baseline BMI was seen between these 2 groups. In a multivariate logistic regression, patients having 5-year data registered in SOReg were 2.2 years older (P < 0.001) than those without, corresponding to an odds ratio (OR) of 1.02 [95% confidence interval (CI) 1.01-1.02]. Other factors increasing the probability of having 5-year data were female sex (OR 1.12, 95% CI 1.01-1.23), T2DM (OR 1.26, 95% CI 1.08-1.46), hypertension (OR 1.16, 95% CI 1.02-1.32), and dyslipidemia (OR 1.34, 95% CI 1.10-1.63) at baseline. The increased number of patients having 3 of the 5 studied comorbidities and being at an older age should reduce the risk for exaggeration of the results.
Ethics
This study was approved by the regional ethical committee of Stockholm, Sweden (2013/535-31/5). 
RESULTS

Weight Change and Waist Circumference
At 5 years, the mean weight loss was 34.5 kg, corresponding to a total body weight loss of 27.7% (men 26.2%, women 28.1%), despite a weight regain (4.8 kg) between 2 and 5 years. Despite this, 3 out of 4 individuals had lost more than 25 kg at 5 years, and 10.2% of the participants had reached a normal BMI (25 or less) ( Table 2) .
At baseline, the waist circumference was 137.8 AE 12.8 cm for men and 124.2 AE 12.4 cm for women, thus well above both normal range and the high-risk levels set by National Institutes of Health (>102 cm for men and >88 cm for women). 9 At 5-year follow-up, there was a significant reduction in waist circumference (26 cm), increasing the percentage of men without a high-risk waist circumference (<102 cm) from 0.1% to 23.7%. Corresponding figures for women (<88 cm) were 1.5% to 25.5%. Absolute values are presented in Table 2 .
Changes in Comorbid Disease
At baseline, 50.3% of all patients reported to be on medication (or CPAP for sleep apnea) for 1 or more of the above specified comorbid diseases. Hypertension was most common (29.7%), followed by depression (24.1%), T2DM (15.5%), dyslipidemia (14.0%), and sleep apnea (9.6%). More men than women had at least 1 comorbid condition (57.5% vs 48.3%; P < 0.001), with sleep apnea, T2DM, and dyslipidemia more frequent in men (P < 0.001 for all), whereas pharmacologically treated depression was more common in women (P < 0.001) ( Table 3) .
Type 2 Diabetes Mellitus
Five years after surgery, the proportion of patients taking medication for T2DM was significantly lower compared with baseline (5.9% and 15.5%, respectively; P < 0.001). Throughout the study period, the prevalence was almost twice as high in men as in women (24.8% to 12.5% at baseline and 9.0% to 4.9% at 5-year follow-up, respectively). Patients with greater weight loss had a greater chance of diabetes remission, whereas high age or high HbA1c at baseline were negative prognostic factors (Table 4 ). In addition, a lower HbA1c at baseline characterized patients experiencing remission of their former T2DM. In terms of new cases of T2DM, 56 (0.2%), 104 (0.4%), and 52 (0.5%) were noted at 1, 2, and 5-year follow-up, respectively.
Hypertension
The number of patients with medication for hypertension was significantly reduced at 5 years, from 29.7% at baseline to 19.5% (P < 0.001). The prevalence was almost twice as high in men as in women (26.7% and 17.3%, respectively) at 5 years (Table 3 ). In the multivariate analysis, older individuals and those with high BMI at baseline had a decreased chance of remission. In contrast, large weight loss was a positive factor (Table 4 ).
Dyslipidemia
The use of medication for dyslipidemia was significantly lower at 5-year follow-up (6.8%, compared with 14.0% at baseline; P < 0.002). Again, more men than women were affected (23.8% vs 10.8%) ( Table 3) . Increased age and high BMI at baseline were negative prognostic factors, whereas large weight loss improved the chance of remission, at least up to 2-year follow-up (Table 4) .
Antidepressant Drug Use
Over the study period, the prevalence of pharmacologically treated depression increased (24.1% to 27.5%; P < 0.001). This was true for both men and women. Women were nearly twice as likely to be treated for depression as men (Table 3) . Male sex and high weight loss were positive prognostic factors (Table 4) .
Sleep Apnea
There was a large reduction of CPAP-treated sleep apnea with a continued improvement at 5-year follow-up (9.6% to 2.6%). The prevalence of sleep apnea at baseline was greater in men than in women (21.3% vs 5.9%), but improvement was seen in both sexes (Table 3) . Large weight loss increased the chance of discontinuing A statistical difference (P < 0.001) was seen in prevalence between men and women for all comorbid diseases at baseline, and between prevalence at baseline and 5 years after surgery (P ¼ 0.002 for hypertension, baseline to 5 years). Data from the Prescribed Drug Registry (PDR) with 100% 5-year follow-up [T2DM (ATC code: A10A, A10B), hypertension (C02, C03, C08, C09), dyslipidemia (C10), or depression (N06A)]. CPAP treatment, whereas high age and high BMI at baseline were negative predictive factors (Table 4) .
Biochemical Biomarkers and Blood Pressure
Glucose Homeostasis
Improved fasting glucose was seen at 1-year follow-up (6.1 to 5.2 mmol/L) and was sustained over time (5.4 mmol/L at 5 years). The percentage of patients with fasting glucose >7.0 mmol/L was reduced from 15.6% to 6.3% at 5 years. In line with this, a significant improvement was seen in HbA1c at 5 years (from 41.8 to 37.7 mmol/ mol), and the number of individuals with an HbA1c >48 mmol/mol was significantly reduced (15.9% to 7.6%). In general, men had poorer glucose control compared with women throughout the study period, with a doubled risk of having pathological values (Table 5 ). There was a significant reduction in fasting glucose and HbA1c both in subjects with and without diabetes.
Blood Pressure
Systolic blood pressure was reduced at 5-year follow-up, and the number of individuals having >140 mm Hg was reduced from 57.9% to 39.3%. A similar reduction was seen in number of individuals with a diastolic blood pressure >90 mm Hg (31.3% to 22.6%). Throughout the study period, more men than women had ongoing pharmacological treatment for hypertension, and despite this, more men had a blood pressure above the normal reference range (Table 5 ). There was a significant reduction in systolic and diastolic blood pressure in both subjects with and without hypertension.
Lipids
An improvement in lipids was seen already at 1-year followup. At 5 years, TGs were reduced from 2.1 to 1.2 mol/L, resulting in a decrease from 34.8% to 13.2% of patients having pathological values. LDL levels were reduced (3.1 to 2.6 mol/L), and a corresponding increase in HDL levels (1.2 to 1.6 mol/L) was seen. The number of individuals with pathological LDL and HDL were significantly reduced (12.2% to 2.9% and 70.9% to 20.8%, respectively); however, a larger proportion of men than women had pathological values (Table 5 ). There was a significant improvement in TG, HDL, and LDL in both subjects with and without dyslipidemia.
CONCLUSIONS
In this large nationwide cohort, primary gastric bypass surgery resulted in substantial weight loss (34.5 kg), corresponding to a total body weight loss of 27.7% at 5-year follow-up. Major improvements in obesity-related comorbid diseases were seen, although relapses did occur between years 2 and 5, parallel to partial weight regain. The most profound changes were seen in sleep apnea and T2DM, where 3 out of 4 individuals had discontinued CPAP treatment, and 2 out of 3 of former diabetic patients were free of any antidiabetic medication at 5-year follow-up. In contrast, 3.4% more patients were on antidepressant treatment during the 5-year follow-up period. In general, high weight loss facilitated remission of comorbid diseases, whereas high age and high BMI at baseline were negative factors. Furthermore, we were able to demonstrate that the overall positive effect upon risk factors, such as HbA1c, lipids, and blood pressure, was applicable to not only patients with disease, but also those without comorbid disease at baseline.
Our data are similar to those previously reported with regard to initial weight loss and reduced waist circumference. We report a 5-year 27.7% loss of the initial weight, which is comparable with the 31.5% weight loss at 3 years in The Longitudinal Assessment of Bariatric Surgery Consortium (LABS), 10 and identical to the 27.7% weight loss reported after 6 years in the Utah study. 3 The Swedish obese subjects (SOS) study reported a 19% reduction in waist circumference, 1 which is similar to the 20.8% reduction seen in the present study, placing a fourth of our patients below the threshold for high risk of metabolic disease. A meta-analysis by Buchwald et al reported a complete remission of T2DM in 74.6% of patients with more than 2 years of follow-up (remission defined as no diabetes medications, a fasting glucose of 5.5 mmol/L, and a HbA1c <52 mmol/mol) after bariatric surgery, 6 which is similar to a remission rate of 67% seen at 5 years in earlier studies, 11, 12 and also the present 62% (defined as no diabetes medication at all). Furthermore, after up to 15 years of follow-up in the SOS study, there were 392 new cases in the control group and 110 in the bariatric surgery group, representing 28.4 and 6.8 new cases per 1000 person-years, respectively. 13 Our data with 1.1 new cases per 1000 person-years (52 new cases during the 5-year period) are significantly better, perhaps reflecting choice of surgical method to be gastric bypass instead of restrictive surgery.
14 In a recent systematic review on bariatric surgery with mean follow-up of 57.8 months, hypertension came into remission in 63% of patients and dyslipidemia in 65%. 15 This is a higher remission rate than seen in the present study; however, our data are in line with those published from the LABS study 10 and somewhat better than those of the SOS study. 1 Notably, high age significantly reduced the chance for remission of hypertension in the present study.
Our results on pharmacological treatment of depression are in contrast to the few previously published studies. In the LABS study, a decrease was seen in pharmacological treatment of depression, from 35.3% of the patients at baseline to 27.5% at 3-year follow-up. 10 Moreover, in a retrospective study where 48.6% of RYGB patients were on antidepressants at baseline, 16% had a decrease or discontinuation of antidepressants after surgery. 16 Although we demonstrate an increase in medication for depression, our 5-year incidence (27.5%) is similar to the postoperative findings in the previous study.
10 Also, we demonstrate an increase in pharmacological treatment which might not reflect actual depressive symptoms. Our results with regard to sleep apnea are in line with a meta-analysis reporting 80.4% remission of sleep apnea after RYGB. 17 Although recurrent disease was seen in 1.1% of patients in the present study, the discontinuation of CPAP treatment continued over the whole study period.
One observation warrants further discussion. Despite the large improvements in comorbid diseases, 42.3% of the studied individuals still required treatment for at least 1 comorbid disease 5 years after surgery. As new-onset cases (although few) in all studied comorbidities were found, continuous follow-up with assessment of treatmentdemanding diseases is necessary.
Strengths of the present study include a large number of participants, all having undergone a standardized and modern surgical intervention for obesity, and the high nationwide coverage (98.5% of all procedures in Sweden). Moreover, SOReg data have been found to be reliable with a very low risk for incorrect values, when systematically validated, or continuously searched for nonlogic or unlikely values. 7 To counter the 45% follow-up rate in SOReg, a cross-reference was done with the PDR, allowing 100% follow-up of medically treated comorbid diseases. Finally, as older patients and those with some of the specific comorbidities were more likely to have 5-year follow-up data than patients not attending a 5-year visit in the sensitivity analysis, the risk for exaggeration of the positive results is reduced.
In summary, this large prospective nationwide study on outcome after primary gastric bypass has demonstrated substantial weight loss and significant improvements in sleep apnea, diabetes, hypertension, and dyslipidemia in both men and women up to 5-year follow-up. However, 42.3% of the included individuals still required treatment for at least 1 comorbid disease 5 years after surgery, making life-long follow-up with assessment of treatment-demanding diseases necessary. The lack of improvement in depression warrants further study.
